奥拉帕利和帕博利珠单抗对具有胚系突变和高肿瘤突变负荷的胰腺腺癌的显著疗效：病例报告及文献综述 - Suppr

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

作者信息

Lundy Joanne, McKay Owen, Croagh Daniel, Ganju Vinod

机构信息

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.

Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.

出版信息

JCO Precis Oncol. 2022 Jan;6:e2100437. doi: 10.1200/PO.21.00437.

DOI:10.1200/PO.21.00437

PMID:35085003

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8830512/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c5/8830512/108a51572086/po-6-e2100437-g001.jpg

相似文献

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

JCO Precis Oncol. 2022 Jan;6:e2100437. doi: 10.1200/PO.21.00437.

[Olaparib and pancreatic cancer: A challenging Lesson].

Bull Cancer. 2019 Sep;106(9):715-716. doi: 10.1016/j.bulcan.2019.07.002. Epub 2019 Aug 6.

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer.

N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

Medicine (Baltimore). 2019 Oct;98(40):e17443. doi: 10.1097/MD.0000000000017443.

Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.

J BUON. 2021 Sep-Oct;26(5):2202.

[New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].

Bull Cancer. 2020 Oct;107(10):961-962. doi: 10.1016/j.bulcan.2020.06.009. Epub 2020 Sep 14.

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).

Ann Surg Oncol. 2022 Sep;29(9):5375-5376. doi: 10.1245/s10434-022-11917-2. Epub 2022 Jun 6.

Olaparib shows promise in multiple tumor types.

Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.

A new targeted treatment for patients with a germline mutation: olaparib in pancreatic cancer.

Future Oncol. 2020 Nov;16(33):2691-2700. doi: 10.2217/fon-2020-0334. Epub 2020 Aug 17.

引用本文的文献

Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.

Oncotarget. 2025 Jun 10;16:427-442. doi: 10.18632/oncotarget.28739.

Case report: Dramatic impact of DNA next generation sequencing results using specific targeted therapies- and .

Front Oncol. 2024 Nov 26;14:1462930. doi: 10.3389/fonc.2024.1462930. eCollection 2024.

Advancing Immunotherapy in Pancreatic Cancer.

Int J Mol Sci. 2024 Oct 28;25(21):11560. doi: 10.3390/ijms252111560.

Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series.

Cancers (Basel). 2024 Oct 9;16(19):3421. doi: 10.3390/cancers16193421.

A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.

Oncotarget. 2024 Oct 11;15:741-747. doi: 10.18632/oncotarget.28659.

Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.

Cancers (Basel). 2023 Dec 21;16(1):56. doi: 10.3390/cancers16010056.

Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction.

Cancers (Basel). 2023 Dec 19;16(1):2. doi: 10.3390/cancers16010002.

Maintenance Treatment for Metastatic Pancreatic Cancer: Balancing Therapeutic Intensity with Tolerable Toxicity.

Cancers (Basel). 2023 Jul 18;15(14):3657. doi: 10.3390/cancers15143657.

New Treatment Options in Metastatic Pancreatic Cancer.

Cancers (Basel). 2023 Apr 17;15(8):2327. doi: 10.3390/cancers15082327.

Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.

J Med Cases. 2022 May;13(5):240-243. doi: 10.14740/jmc3918. Epub 2022 May 7.

本文引用的文献

The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial.

Endosc Ultrasound. 2021 Sep-Oct;10(5):335-343. doi: 10.4103/EUS-D-20-00230.

Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives.

Front Oncol. 2021 Jun 23;11:682872. doi: 10.3389/fonc.2021.682872. eCollection 2021.

Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.

Cancers (Basel). 2021 Jun 22;13(13):3119. doi: 10.3390/cancers13133119.

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.

JAMA Oncol. 2021 May 1;7(5):739-743. doi: 10.1001/jamaoncol.2020.7684.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

Cancer Statistics, 2021.

CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.

Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.

J Pers Med. 2020 Nov 27;10(4):252. doi: 10.3390/jpm10040252.

Enhancing the efficacy of immunotherapy using radiotherapy.

Clin Transl Immunology. 2020 Sep 10;9(9):e1169. doi: 10.1002/cti2.1169. eCollection 2020.

KRAS Inhibition with Sotorasib in Advanced Solid Tumors.

N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献